{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:11:53Z","timestamp":1792685513486,"version":"4.5.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.prp.2026.156452","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T15:53:55Z","timestamp":1774108435000},"page":"156452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Solid lipid nanoparticles for targeted drug delivery in breast cancer: Biointerface interactions, therapeutic potential, and translational challenges"],"prefix":"10.1016","volume":"282","author":[{"given":"Abhay","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6352-0535","authenticated-orcid":false,"given":"Rohit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2026.156452_bib2","article-title":"An overview of receptor-targeted nanotechnological approaches for the treatment of metastatic breast cancer","author":"Nayak","year":"2024","journal-title":"Curr. Nanomed."},{"key":"10.1016\/j.prp.2026.156452_bib3","article-title":"Nanotechnology-based drug delivery for breast cancer treatment: current applications and future directions","author":"Samad","year":"2025","journal-title":"Eur. J. Med. Chem. Rep."},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib4","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"19","key":"10.1016\/j.prp.2026.156452_bib5","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.3390\/ijms26199714","article-title":"Triple-negative breast cancer unveiled: bridging science, treatment strategy, and economic aspects","volume":"26","author":"Lebedeva","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156452_bib6","first-page":"128","article-title":"Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN)","volume":"4","author":"Cao","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.36346\/sarjbab.2025.v07i06.003","article-title":"Breast cancer in Iraq: a comprehensive review of disease burden, risk factors, and healthcare response","volume":"7","author":"Ali","year":"2025","journal-title":"South Asian Res J. Bio Appl. Biosci."},{"issue":"4","key":"10.1016\/j.prp.2026.156452_bib8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med"},{"key":"10.1016\/j.prp.2026.156452_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"15 Pt 1","key":"10.1016\/j.prp.2026.156452_bib10","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.prp.2026.156452_bib11","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib12","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3390\/pharmaceutics15061593","article-title":"Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review","volume":"15","author":"Viegas","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156452_bib13","unstructured":"Fogarassy G. Risk factors and prevention of anthracycline-related heart failure: University of Szeged (Hungary); 2020."},{"issue":"7","key":"10.1016\/j.prp.2026.156452_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev. Med."},{"key":"10.1016\/j.prp.2026.156452_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919833519","article-title":"HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance","volume":"11","author":"Pernas","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156452_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.prp.2026.156452_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib20","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41579-020-0420-1","article-title":"Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections","volume":"19","author":"Makabenta","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3390\/biom12060784","article-title":"Nano-based approved pharmaceuticals for cancer treatment: present and future challenges","volume":"12","author":"Rodriguez","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111602","article-title":"Advances in nanoparticle-based radiotherapy for cancer treatment","volume":"28","author":"He","year":"2025","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib25","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156452_bib26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"64","author":"Mehnert","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.prp.2026.156452_bib27","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3390\/pharmaceutics15082065","article-title":"Overview of solid lipid nanoparticles in breast cancer therapy","volume":"15","author":"Mo","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156452_bib28","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jddst.2017.04.003","article-title":"Influence of state and crystallinity of lipid matrix on physicochemical properties and permeation of capsaicin-loaded lipid nanoparticles for topical delivery","volume":"39","author":"Teeranachaideekul","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"8","key":"10.1016\/j.prp.2026.156452_bib29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/pharmaceutics17081079","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers for anticancer phytochemical delivery: advances, challenges, and future prospects","volume":"17","author":"Jacob","year":"2025","journal-title":"Pharmaceutics"},{"issue":"41","key":"10.1016\/j.prp.2026.156452_bib30","doi-asserted-by":"crossref","first-page":"19679","DOI":"10.1021\/acsanm.5c03503","article-title":"Theranostic applications of tailored lipid-based nanoparticles as drug delivery systems for cancer treatment","volume":"8","author":"Gupta","year":"2025","journal-title":"ACS Appl. Nano Mater."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib31","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"Muller","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.prp.2026.156452_bib32","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2500 from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS nano"},{"key":"10.1016\/j.prp.2026.156452_bib33","article-title":"Co-delivery of doxorubicin and hydroxychloroquine via chitosan\/alginate nanoparticles for blocking autophagy and enhancing chemotherapy in breast cancer therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.prp.2026.156452_bib34","series-title":"Nanotechnology For Medicine","first-page":"318","article-title":"Nanoparticles for Antibiotics","author":"Sultan","year":"2025"},{"issue":"20","key":"10.1016\/j.prp.2026.156452_bib35","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.1039\/D4RA02639J","article-title":"Nanoscale strides: exploring innovative therapies for breast cancer treatment","volume":"14","author":"Mugundhan","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.prp.2026.156452_bib36","series-title":"Nanotechnologies for Drug Delivery and Biopharmaceutical Development","author":"Khanna","year":"2025"},{"issue":"20","key":"10.1016\/j.prp.2026.156452_bib37","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.1039\/D4RA02639J","article-title":"Nanoscale strides: exploring innovative therapies for breast cancer treatment","volume":"14","author":"Mugundhan","year":"2024","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.prp.2026.156452_bib38","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3390\/pr12091970","article-title":"Innovative and patented liposome-based drug carriers","volume":"12","author":"Ili\u0107-Stojanovi\u0107","year":"2024","journal-title":"Processes"},{"issue":"45","key":"10.1016\/j.prp.2026.156452_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202407793","article-title":"Toward the integration of machine learning and molecular modeling for designing drug delivery nanocarriers","volume":"36","author":"Gao","year":"2024","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib40","article-title":"Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential","volume":"25","author":"Shah","year":"2014","journal-title":"J. Phys. Sci."},{"key":"10.1016\/j.prp.2026.156452_bib41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jcis.2017.05.038","article-title":"Effect of binary solid lipid matrix of wax and triglyceride on lipid crystallinity, drug-lipid interaction and drug release of ibuprofen-loaded solid lipid nanoparticles (SLN) for dermal delivery","volume":"504","author":"Chantaburanan","year":"2017","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.prp.2026.156452_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121044","article-title":"Mitoxantrone-loaded lipid nanoparticles for breast cancer therapy\u2013quality-by-design approach and efficacy assessment in 2D and 3D in vitro cancer models","volume":"607","author":"Granja","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib43","doi-asserted-by":"crossref","DOI":"10.1515\/ntrev-2022-0517","article-title":"Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers\u2019 development","volume":"12","author":"Mohammed","year":"2023","journal-title":"Nanotechnol. Rev."},{"issue":"34","key":"10.1016\/j.prp.2026.156452_bib44","doi-asserted-by":"crossref","first-page":"30015","DOI":"10.1021\/acsomega.2c03023","article-title":"Radiolabeled trastuzumab solid lipid nanoparticles for breast cancer cell: in vitro and in vivo studies","volume":"7","author":"Ozgenc","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.prp.2026.156452_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01932691.2025.2496388","article-title":"Unlocking the multifaceted potential of lipid-based dispersion as a drug carrier: targeted applications and stability improvement strategies","author":"Puri","year":"2025","journal-title":"J. Dispers. Sci. Technol."},{"issue":"2","key":"10.1016\/j.prp.2026.156452_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/0118764029272246231120045443","article-title":"Advances in neutrophil cell membrane-coated nano drug delivery systems: a comprehensive review","volume":"16","author":"Bajwa","year":"2024","journal-title":"Micro Nanosyst."},{"issue":"12","key":"10.1016\/j.prp.2026.156452_bib47","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/pharmaceutics16121521","article-title":"Effect of lipid nanoparticle physico-chemical properties and composition on their interaction with the immune system","volume":"16","author":"Catenacci","year":"2024","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.34172\/apb.2023.056","article-title":"An overview of nanostructured lipid carriers and its application in drug delivery through different routes","volume":"13","author":"Khan","year":"2022","journal-title":"Adv. Pharm. Bull."},{"issue":"19","key":"10.1016\/j.prp.2026.156452_bib49","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.3390\/ijms251910712","article-title":"Solid lipid nanoparticles, an alternative for the treatment of triple-negative breast cancer","volume":"25","author":"Llaguno-Munive","year":"2024","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156452_bib50","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/pharmaceutics15051333","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) Prepared by microwave and ultrasound-assisted synthesis: promising green strategies for the nanoworld","volume":"15","author":"Lopez","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/pharmaceutics15030893","article-title":"Recent Preclinical and Clinical Progress in Liposomal Doxorubicin","volume":"15","author":"Aloss","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf101","article-title":"Pegylated liposomal doxorubicin+ cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial","volume":"30","author":"Tang","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2026.156452_bib53","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.2147\/IJN.S488545","article-title":"Nanoemulsions Based Therapeutic Strategies: Enhancing Targeted Drug Delivery against Breast Cancer Cells","volume":"20","author":"Izadiyan","year":"2025","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.prp.2026.156452_bib54","article-title":"Solid lipid nanoparticles: an effective lipid-based technology for cancer treatment","volume":"86","author":"Akanda","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"4","key":"10.1016\/j.prp.2026.156452_bib55","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3109\/10717544.2015.1092183","article-title":"Lipid-based nanocarriers for breast cancer treatment\u2013comprehensive review","volume":"23","author":"Talluri","year":"2016","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib57","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1038\/s41598-025-90107-y","article-title":"Advancing triple-negative breast cancer treatment through peptide decorated solid lipid nanoparticles for paclitaxel delivery","volume":"15","author":"Rahdari","year":"2025","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.prp.2026.156452_bib58","doi-asserted-by":"crossref","first-page":"10068","DOI":"10.3390\/ijms231710068","article-title":"Lipid-based nanoparticles as a pivotal delivery approach in triple negative breast cancer (TNBC) therapy","volume":"23","author":"Chaudhuri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.prp.2026.156452_bib59","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41563-020-0755-z","article-title":"The dose threshold for nanoparticle tumour delivery","volume":"19","author":"Ouyang","year":"2020","journal-title":"Nat. Mater."},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib60","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.nano.2017.04.009","article-title":"Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting","volume":"13","author":"Tang","year":"2017","journal-title":"Nanomedicine"},{"issue":"8","key":"10.1016\/j.prp.2026.156452_bib61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/1061186X.2024.2356735","article-title":"Folic acid modified precision nanocarriers: charting new frontiers in breast cancer management beyond conventional therapies","volume":"32","author":"Nehal","year":"2024","journal-title":"J. Drug Target"},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/molecules28031151","article-title":"Transporter-Mediated Drug Delivery","volume":"28","author":"Gyimesi","year":"2023","journal-title":"Molecules"},{"issue":"47","key":"10.1016\/j.prp.2026.156452_bib63","doi-asserted-by":"crossref","first-page":"40293","DOI":"10.1021\/acsnano.5c11721","article-title":"Endosomal Escape of Lipid Nanoparticles: A Perspective on the Literature Data","volume":"19","author":"Pei","year":"2025","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib64","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/pharmaceutics14030574","article-title":"Drug Delivery Strategies and Biomedical Significance of Hydrogels: Translational Considerations","volume":"14","author":"Raina","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.prp.2026.156452_bib65","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2174\/1389201023666220617152334","article-title":"New Era on combining both imaging and drug delivery to treat cancer","volume":"24","author":"Siafaka","year":"2023","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/biochem5030026","article-title":"Therapeutic Potential of Essential Oils and Their Bioactive Compounds Against Colon Cancer: Focus on Colon-Specific Micro-and Nanocarriers","volume":"5","author":"Gvozdeva","year":"2025","journal-title":"BioChem"},{"issue":"02","key":"10.1016\/j.prp.2026.156452_bib67","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1055\/s-0042-1751036","article-title":"Lipid-based nanocarrier systems for drug delivery: Advances and applications","volume":"4","author":"Zhao","year":"2022","journal-title":"Pharm. Fronts"},{"issue":"1-2","key":"10.1016\/j.prp.2026.156452_bib68","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","article-title":"Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products","volume":"366","author":"Pardeike","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.prp.2026.156452_bib69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156452_bib70","first-page":"1","article-title":"Vacuum compression-molded polyvinyl alcohol microneedles for sustained three-day transdermal delivery of palonosetron hydrochloride","author":"Ghosh","year":"2025","journal-title":"Drug Deliv. Transl. Res"},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib71","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6253978","article-title":"Anti-CD44 and EGFR dual-targeted solid lipid nanoparticles for delivery of doxorubicin to triple-negative breast cancer cell line: preparation, statistical optimization, and in vitro characterization","volume":"2022","author":"Darabi","year":"2022","journal-title":"Biomed. Res Int"},{"issue":"37","key":"10.1016\/j.prp.2026.156452_bib72","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.2174\/0113816128319233240725103706","article-title":"Advancements in solid lipid nanoparticles and nanostructured lipid carriers for breast cancer therapy","volume":"30","author":"Marwah","year":"2024","journal-title":"Curr. Pharm. Des."},{"issue":"20","key":"10.1016\/j.prp.2026.156452_bib73","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.3390\/ijms222011300","article-title":"Stimulus-responsive smart nanoparticles-based CRISPR-Cas delivery for therapeutic genome editing","volume":"22","author":"Naeem","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12951-023-01889-0","article-title":"Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment","volume":"21","author":"Zhang","year":"2023","journal-title":"J. Nanobiotechnology"},{"issue":"19","key":"10.1016\/j.prp.2026.156452_bib75","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.2174\/0109298673285334240112104709","article-title":"Advanced targeted drug delivery of bioactive agents fortified with graft chitosan in management of cancer: a review","volume":"32","author":"Begum","year":"2025","journal-title":"Curr. Med Chem."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib76","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1038\/s41598-024-57296-4","article-title":"Dual pH\/redox-responsive hyperbranched polymeric nanocarriers with TME-trigger size shrinkage and charge reversible ability for amplified chemotherapy of breast cancer","volume":"14","author":"Badparvar","year":"2024","journal-title":"Sci. Rep."},{"issue":"1-2","key":"10.1016\/j.prp.2026.156452_bib77","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","article-title":"Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products","volume":"366","author":"Pardeike","year":"2009","journal-title":"Int J. Pharm."},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib78","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/157016311796799062","article-title":"20 years of lipid nanoparticles (SLN & NLC): present state of development & industrial applications","volume":"8","author":"H Muller","year":"2011","journal-title":"Curr. Drug Discov. Technol."},{"issue":"20","key":"10.1016\/j.prp.2026.156452_bib79","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.3390\/molecules25204781","article-title":"Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method","volume":"25","author":"Duong","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.prp.2026.156452_bib80","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ijbiomac.2020.08.036","article-title":"Folic acid functionalized starch encapsulated green synthesized copper oxide nanoparticles for targeted drug delivery in breast cancer therapy","volume":"164","author":"Mariadoss","year":"2020","journal-title":"Int J. Biol. Macromol."},{"key":"10.1016\/j.prp.2026.156452_bib81","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/9783527841165.ch14","article-title":"Nanoparticle-based therapeutics for triple negative breast cancer","author":"Egebe","year":"2023","journal-title":"Drug Ther. Dev. Triple Negat. Breast Cancer"},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib82","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2015011592","article-title":"Polymeric drug-delivery systems: role in P-gp Efflux system inhibition","volume":"32","author":"Gupta","year":"2015","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"issue":"5","key":"10.1016\/j.prp.2026.156452_bib83","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/molecules27051543","article-title":"Perspectives and prospective on solid lipid nanoparticles as drug delivery systems","volume":"27","author":"Madkhali","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib84","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of curcumin: problems and promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol. Pharm."},{"issue":"2024","key":"10.1016\/j.prp.2026.156452_bib85","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/pharmaceutics16040481","article-title":"Nasal delivery to the brain: harnessing nanoparticles for effective drug transport","volume":"16","author":"Gandhi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156452_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.688070","article-title":"Surface PEGylated cancer cell membrane-coated nanoparticles for codelivery of curcumin and doxorubicin for the treatment of multidrug resistant esophageal carcinoma","volume":"9","author":"Gao","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib87","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/pharmaceutics15061611","article-title":"Critical review in designing plant-based anticancer nanoparticles against hepatocellular carcinoma","volume":"15","author":"Basu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib88","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid. Ther."},{"issue":"4","key":"10.1016\/j.prp.2026.156452_bib89","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.3390\/ijms24043375","article-title":"Research status and prospect of non-viral vectors based on siRNA: a review","volume":"24","author":"Tong","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156452_bib90","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.2147\/IJN.S541061","article-title":"Advancing cancer immunotherapy using lipid nanoparticle-based approaches","volume":"20","author":"Prazeres","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.prp.2026.156452_bib91","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2017.11.023","article-title":"Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review","volume":"112","author":"Garc\u00eas","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"21","key":"10.1016\/j.prp.2026.156452_bib92","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.2174\/1381612829666230803111120","article-title":"Current state of lipid nanoparticles (SLN and NLC) for skin applications","volume":"29","author":"Eroglu","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.prp.2026.156452_bib93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.scp.2017.07.002","article-title":"Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery","volume":"6","author":"Ganesan","year":"2017","journal-title":"Sustain. Chem. Pharm."},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib94","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1208\/s12249-015-0384-z","article-title":"Effects of formulation variables on the particle size and drug encapsulation of imatinib-loaded solid lipid nanoparticles","volume":"17","author":"Gupta","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.prp.2026.156452_bib95","series-title":"Natural Polymeric Materials based Drug Delivery Systems in Lung Diseases","first-page":"25","article-title":"Natural Polymers for Drugs Delivery","author":"Manjit","year":"2023"},{"issue":"19","key":"10.1016\/j.prp.2026.156452_bib96","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.3390\/polym13193307","article-title":"Application of Non-Viral Vectors in Drug Delivery and Gene Therapy","volume":"13","author":"Ren","year":"2021","journal-title":"Polym. (Basel)"},{"key":"10.1016\/j.prp.2026.156452_bib97","article-title":"Nanomedicine marvels: crafting the future of cancer therapy with innovative statin nano-formulation strategies","author":"Jirandehi","year":"2024","journal-title":"Nanoscale Adv."},{"issue":"10","key":"10.1016\/j.prp.2026.156452_bib98","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1039\/D0BM00015A","article-title":"Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy","volume":"8","author":"Ahir","year":"2020","journal-title":"Biomater. Sci."},{"issue":"10","key":"10.1016\/j.prp.2026.156452_bib99","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.3390\/cimb44100341","article-title":"Lipid nanoparticles: a novel gene delivery technique for clinical application","volume":"44","author":"Mashima","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.prp.2026.156452_bib100","article-title":"Thiomer-coated solid lipid nanoparticles for the glutathione and temperature-responsive drug delivery against breast cancer","volume":"114","author":"Qureshi","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2026.156452_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.125142","article-title":"Targeted delivery of DAPT using dual antibody functionalized solid lipid nanoparticles for enhanced anti-tumour activity against triple negative breast cancer","volume":"670","author":"Kumari","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.prp.2026.156452_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114406","article-title":"Sunitinib lipid nanoparticles remodel tumor vasculature to synergize with two-stage radiotherapy for enhanced radiosensitivity in breast Cancer","volume":"389","author":"Li","year":"2026","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.prp.2026.156452_bib103","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1021\/cr5004198","article-title":"Nanoparticles in photodynamic therapy","volume":"115","author":"Lucky","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.prp.2026.156452_bib104","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.2147\/IJN.S388996","article-title":"Combined Photodynamic and Photothermal Therapy and Immunotherapy for Cancer Treatment: A Review","volume":"17","author":"Kong","year":"2022","journal-title":"Int J. Nanomed."},{"issue":"10","key":"10.1016\/j.prp.2026.156452_bib105","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s13346-024-01638-2","article-title":"Lipid nanoparticles-based RNA therapies for breast cancer treatment","volume":"14","author":"Serpico","year":"2024","journal-title":"Drug Deliv. Transl. Res"},{"issue":"47","key":"10.1016\/j.prp.2026.156452_bib106","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib107","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biotech11010006","article-title":"Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer","volume":"11","author":"Kanvinde","year":"2022","journal-title":"BioTech. (Basel)"},{"key":"10.1016\/j.prp.2026.156452_bib108","series-title":"Smart micro-and nanomaterials for drug delivery","author":"Behera","year":"2024"},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib109","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/nnm.15.193","article-title":"Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy","volume":"11","author":"Bhargava-Shah","year":"2016","journal-title":"Nanomed. (Lond. )"},{"issue":"9","key":"10.1016\/j.prp.2026.156452_bib110","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1021\/acs.molpharmaceut.9b00797","article-title":"Hybrid Lipid Polymer Nanoparticles for Combined Chemo- and Photodynamic Therapy","volume":"16","author":"N'Diaye","year":"2019","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib111","doi-asserted-by":"crossref","first-page":"228","DOI":"10.20892\/j.issn.2095-3941.2017.0052","article-title":"Recent progress on nanoparticle-based drug delivery systems for cancer therapy","volume":"14","author":"Xin","year":"2017","journal-title":"Cancer Biol. Med"},{"issue":"10","key":"10.1016\/j.prp.2026.156452_bib112","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.2174\/1567201819666220117102658","article-title":"Lipid-based Nanoparticles for the Targeted Delivery of Anticancer Drugs: A Review","volume":"19","author":"Khodaverdi","year":"2022","journal-title":"Curr. Drug Deliv."},{"issue":"6","key":"10.1016\/j.prp.2026.156452_bib113","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.prp.2026.156452_bib114","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1208\/s12249-016-0606-z","article-title":"Improved Method for Solid Lipid Nanoparticle Preparation Based on Hot Microemulsions: Preparation, Characterization, Cytotoxicity, and Hemocompatibility Evaluation","volume":"18","author":"Kotmakci","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"14","key":"10.1016\/j.prp.2026.156452_bib115","doi-asserted-by":"crossref","first-page":"6045","DOI":"10.1039\/C5NR00733J","article-title":"Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies","volume":"7","author":"Fornaguera","year":"2015","journal-title":"Nanoscale"},{"issue":"4","key":"10.1016\/j.prp.2026.156452_bib116","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding pharmaceutical quality by design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.prp.2026.156452_bib117","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41565-024-01833-9","article-title":"Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles","volume":"20","author":"O'Brien Laramy","year":"2025","journal-title":"Nat. Nanotechnol."},{"issue":"4","key":"10.1016\/j.prp.2026.156452_bib118","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/nnm-2018-0278","article-title":"Solid lipid nanoparticles for ocular delivery of isoniazid: evaluation, proof of concept and in vivo safety & kinetics","volume":"14","author":"Singh","year":"2019","journal-title":"Nanomed. (Lond. )"},{"key":"10.1016\/j.prp.2026.156452_bib119","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/B978-0-323-95253-8.00018-8","article-title":"Recent advances in supramolecular organic nanostructures for drug delivery applications","author":"More","year":"2023","journal-title":"Adv. Nano Biochem."},{"issue":"1","key":"10.1016\/j.prp.2026.156452_bib120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41579-020-0420-1","article-title":"Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections","volume":"19","author":"Makabenta","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"9","key":"10.1016\/j.prp.2026.156452_bib121","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.prp.2026.156452_bib122","first-page":"1","article-title":"Advances in microfluidic and artificial intelligence-assisted design of liposomes for drug delivery applications","author":"Has","year":"2025","journal-title":"J. Liposome Res"},{"issue":"8","key":"10.1016\/j.prp.2026.156452_bib123","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/pharmaceutics17081079","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers for anticancer phytochemical delivery: advances, challenges, and future prospects","volume":"17","author":"Jacob","year":"2025","journal-title":"Pharmaceutics"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:38:41Z","timestamp":1785508721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":123,"alternative-id":["S0344033826001032"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156452","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Solid lipid nanoparticles for targeted drug delivery in breast cancer: Biointerface interactions, therapeutic potential, and translational challenges","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156452"}}